Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.

Saved in:
Bibliographic Details
Title: Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.
Authors: Moussa MJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Internal Medicine Residency Program, Department of Medicine, Baylor College of Medicine, Houston, TX., Andreev-Drakhlin AY; Genentech, South San Francisco, CA., Venkatesan AM; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX., Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Shah AY; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Adriazola AC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shaw L; Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lin JK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Guo CC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Alhalabi O; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: JCO precision oncology [JCO Precis Oncol] 2026 Mar; Vol. 10 (3), pp. e2500772. Date of Electronic Publication: 2026 Mar 30.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-4284
DOI:10.1200/PO-25-00772